Share this article
Share this article
Experts outline potential for improved stroke patient outcomes, cost effectiveness through use of the ReStore device in the rehabilitation setting
MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ ReWalk Robotics, Ltd. (Nasdaq: RWLK) ( ReWalk or the Company ), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReStore Soft Exo-Suit was the subject of a recent Medtech Innovation Briefing (MIB) by the UK s National Institute for Health and Care Excellence (NICE). These briefings are designed to support National Health Services (NHS) and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies.
NICE backs selective internal radiation therapy for advanced liver cancer
2nd March 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended selective internal radiation therapy (SIRT) for the treatment of advanced liver cancer in final draft guidance.
NICE’s draft guidance recommends the use of SIR-Spheres – made by SIRTEX – and TheraSphere – made by Boston Scientific – for treating advanced liver cancer that can’t be removed surgically and when transarterial therapy is not appropriate.
The recommendation also specifies that these two therapies should only be considered for people with Child-Pugh grade A liver impairment.
Despite limited clinical trial data for SIRTs compared with other treatment options, NICE’s appraisal committee concluded that SIRT may have fewer and more manageable side effects compared to systemic therapy sorafenib.
I m not depressed, I m menopausal – so why did I have to fight to get HRT?
2 Mar, 2021 01:51 AM
7 minutes to read
OPINION:
Last summer, I had a few socially distanced drinks on the beach with friends old and new.
As the sky darkened and wine loosened our tongues, chat moved to the menopause. I talked about waking up at 2am, my chest drenched in sweat, my heart racing so fast I feared for my life.
I would remain in that state till 6am and then drop off for two hours until the alarm pulled me out of the sweetest sleep.
NICE recommends routine funding for Novartis’ Kisqali
26th February 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended routine access to Novartis’ Kisqali in certain advanced breast cancer patients.
NICE’s draft guidance recommends Kisqali (ribociclib) in combination with fulvestrant for the treatment of locally advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative.
It will be routinely available on the NHS for adults who have had previous endocrine therapy and where exemestane plus everolimus is the most appropriate alternative treatment.
Kisqali is taken as a once-daily pill and belongs to a class of drugs known as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors.